Teleflex Incorporated (NYSE:TFX), a leading global provider of
medical technologies, today announced the upcoming full market
release of the Advanced Tissue Control (ATC) feature on its unified
UroLift
™ 2 System platform designed for the
treatment of benign prostatic hyperplasia (BPH) symptoms in men
with all prostate types up to 100g. The UroLift™ 2 System with
Advanced Tissue Control (UroLift™ 2 ATC) has received FDA
clearance, marking a significant advancement in BPH care.
The UroLift™ 2 System is a market leader and proven
minimally invasive treatment for BPH that provides an effective
alternative to BPH medications and major surgery.1,2 The UroLift™ 2
ATC represents a breakthrough in BPH treatment, with its adaptable
design that enables physicians to customize treatments to each
patient’s unique anatomy and allows a personalized approach to help
maximize effectiveness.
The UroLift™ 2 ATC System offers physicians
enhanced confidence, improved control of obstructive tissue and
targeting accuracy through tissue control wings and laser-etched
needle markers designed to make tissue manipulation and implant
delivery more precise.3 A streamlined delivery system, utilizing
one handle per procedure and individual implant cartridges, also
ensures increased physician comfort and improves efficiency during
the procedure.3
“UroLift™ 2 ATC optimizes enlarged prostate
treatment by providing urologists with unparalleled confidence and
customization capabilities,” said Jake Newman, President, The
Americas, Teleflex. “The UroLift™ 2 System with ATC offers a
comprehensive solution for BPH care, combining cutting-edge
technology with proven clinical outcomes.1 Our innovative platform
streamlines procedures and eliminates the need to transition
between platforms during a procedure. Enhanced features, including
greater and more consistent implant compression and reduced waste,
will help drive outcomes and efficiency in healthcare
delivery.”
Brian Wilkins, Vice President of Research and
Development for Teleflex Interventional Urology, added, “The
UroLift™ 2 ATC is designed to deliver the same proven effectiveness
of the UroLift™ System, with significant enhancements on a unified
UroLift™ 2 platform. Based on physician feedback, it maintains the
efficacy of the UroLift™ System, improves overall performance, and
offers physicians the advantage of efficiently treating a broader
range of patients.3 This expanded capability offered by UroLift™ 2
ATC opens new avenues for patient care.”
“The UroLift™ 2 ATC is a game-changer. Bringing the
enhanced tissue control capabilities onto the innovative and proven
UroLift™ 2 platform allows me to deliver unparalleled precision to
treat a broad spectrum of patients and anatomies. It has
transformed my approach to BPH care,” said Dr. Adam Craig Thomas of
Parkview Physicians Group Urology in Fort Wayne, Indiana.
Dr. Mark Pe with Genesis Urology in San Diego,
California added, “I find it immensely helpful to have UroLift™ 2
ATC stocked and readily available at every procedure in case
additional tissue control is needed. It ensures I’m always equipped
to treat a broad range of patients with unique prostate types and
anatomies.”
To learn more about UroLift™ 2 ATC, visit
UroLift.com.
About the UroLift™ SystemThe
UroLift™ System is a minimally invasive treatment for lower urinary
tract symptoms due to benign prostatic hyperplasia (BPH). It is
indicated for the treatment of symptoms of an enlarged prostate up
to 100cc in men 45 years or older (50 years outside U.S.). The
UroLift™ System permanent implants, which can be delivered during
an outpatient procedure,4 relieve prostate obstruction without
heating, cutting, destruction of, or removing prostate tissue. The
UroLift™ System can be used to treat a broad spectrum of anatomies,
including obstructive median lobe.5-6 It is the only leading BPH
procedure shown to not cause new onset, sustained erectile or
ejaculatory dysfunction.*7-8 A study conducted over 5 years showed
a low retreatment rate of about 2-3% per year, or a total of 13.6%
over the course of the study, demonstrating UroLift™ System
durability.1 Most common side effects are temporary and can include
hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence.9 Rare side effects, including bleeding and infection,
may lead to a serious outcome and may require intervention.
Individual results may vary. The prostatic urethral lift procedure
(using the UroLift™ System) is recommended for the treatment of BPH
in both the 2021 American Urological Association and 2022 European
Association of Urology clinical guidelines. 475,000 men have been
treated with the UroLift™ System in select markets worldwide.10
Learn more at www.UroLift.com. Rx only.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet
clinical needs – to benefit patients and healthcare providers. Our
portfolio is diverse, with solutions in the fields of vascular
access, interventional cardiology and radiology, anesthesia,
emergency medicine, surgical, urology and respiratory care.
Teleflex employees worldwide are united in the understanding that
what we do every day makes a difference. For more information,
please visit teleflex.com.
Teleflex is the home of Arrow™, Deknatel™, LMA™,
Pilling™, QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands
united by a common sense of purpose.
Forward-Looking Statements Any
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management’s current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA,
Pilling, QuikClot, Rüsch, UroLift and Weck are trademarks or
registered trademarks of Teleflex Incorporated or its affiliates,
in the U.S. and/or other countries. All other trademarks are the
property of their respective owners. © 2024 Teleflex Incorporated.
All rights reserved. MAC02839-01 Rev A
References:
- Roehrborn, Can J Urol 2017
- U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22
FINAL), which is in part based on Symphony Health PatientSource®
2018-21, as is and with no representations/warranties, including
accuracy or completeness.
- Data on file
- Shore, Can J Urol 2014
- Rukstalis, Prostate Cancer and Prostatic Dis 2018
- UroLift System Instructions for Use
- AUA BPH Guidelines 2003, 2020
- McVary, Urology 2019
- Roehrborn, J Urology 2013
- Management estimate based on product sales as of January 2024.
Data on file Teleflex Interventional Urology.
*No instances of new, sustained erectile or
ejaculatory dysfunction in the L.I.F.T. pivotal study
Contacts:TeleflexLawrence
KeuschVice President, Investor Relations and Strategy
Development
investor.relations@teleflex.com610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jul 2023 to Jul 2024